惠程科技(002168) - 2025 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2025 was ¥60,760,002.19, representing a 94.47% increase compared to ¥31,244,678.22 in the same period last year[3]. - The net profit attributable to shareholders was -¥16,847,844.06, an improvement of 55.23% from -¥37,631,428.42 year-on-year[3]. - The net cash flow from operating activities was ¥7,397,522.36, a significant turnaround from -¥15,189,843.61 in Q1 2024, marking a 148.70% increase[3]. - Total operating revenue for the current period reached ¥60,760,002.19, a significant increase from ¥31,244,678.22 in the previous period, representing a growth of approximately 94%[20]. - Net profit for the current period was reported at -¥14,278,413.00, an improvement compared to -¥38,631,124.20 in the previous period, indicating a reduction in losses[21]. - The company reported a total comprehensive loss of -¥15,995,045.19, compared to -¥38,631,593.35 in the previous period, indicating a significant reduction in comprehensive losses[22]. Assets and Liabilities - Total assets increased by 22.79% to ¥971,550,337.54 from ¥791,218,924.57 at the end of the previous year[3]. - The total liabilities amounted to ¥1,014,273,216.06, up from ¥830,085,133.93, marking an increase of about 22%[18]. - The total equity attributable to the parent company was reported at -¥73,387,982.08, worsening from -¥54,823,505.99 in the previous period[18]. - Current assets total 497,751,799.23 RMB, up from 345,293,966.48 RMB at the start of the period[17]. - The company’s non-current assets total 473,798,538.31 RMB, up from 445,924,958.09 RMB, reflecting a growth of about 6.3%[17]. Cash Flow - The net cash flow from investing activities decreased significantly by 98.33% to -¥62,587.61, reflecting reduced investment expenditures[11]. - Cash received from sales of goods and services was ¥70,952,859.07, an increase from ¥38,560,150.62 in the previous period, reflecting a growth of approximately 84%[22]. - Cash inflow from financing activities totaled $8,110,000.00, down from $44,200,000.00 in the prior period[23]. - Net cash flow from financing activities was -$20,384,635.13, compared to -$4,206,343.02 in the previous period[23]. - The net increase in cash and cash equivalents was -$13,077,209.11, compared to -$23,165,696.61 last year[23]. - The ending balance of cash and cash equivalents was $3,734,295.38, down from $40,818,377.99 in the previous period[23]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 37,451[13]. - The largest shareholder, Chongqing Green Development City Construction Co., Ltd., holds 12.15% of shares, totaling 95,303,911 shares[13]. Strategic Developments - The company aims to leverage industry development opportunities and improve overall operational performance to mitigate delisting risk due to negative net profit and equity[3]. - The company plans to focus on core business development and explore potential market demands to enhance profitability[3]. - The company acquired 51% of Chongqing Rui'en Pharmaceutical Co., Ltd. for a cash consideration of 47 million RMB, enhancing its strategic development in the pharmaceutical sector[14]. Operational Metrics - Sales expenses surged by 563.78% to ¥21,266,791.83, attributed to the new biopharmaceutical segment's revenue[9]. - Research and development expenses increased to ¥4,045,215.52 from ¥3,476,303.75, showing a growth of approximately 16%[21]. - The company reported a significant increase in other receivables, which rose to 32,218,288.75 RMB from 7,896,312.46 RMB, marking an increase of over 300%[16]. - Inventory has risen to 99,043,701.55 RMB, compared to 83,575,141.59 RMB previously, indicating a growth of about 18.5%[17]. - Short-term borrowings increased to 138,000,000.00 RMB from 130,130,931.91 RMB, showing a rise of approximately 6.4%[17]. Audit Status - The first quarter report was not audited, indicating potential areas for further scrutiny[24].